These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 33443072

  • 1. Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T.
    Yusufi N, Wurzer A, Herz M, D'Alessandria C, Feuerecker B, Weber W, Wester HJ, Nekolla S, Eiber M.
    J Nucl Med; 2021 Aug 01; 62(8):1106-1111. PubMed ID: 33443072
    [Abstract] [Full Text] [Related]

  • 2. An Intrapatient Dosimetry Comparison of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Rinscheid A, Gäble A, Wienand G, Pfob C, Dierks A, Kircher M, Trepel M, Weckermann D, Lapa C, Bundschuh RA.
    J Nucl Med; 2023 Dec 01; 64(12):1918-1924. PubMed ID: 37770108
    [Abstract] [Full Text] [Related]

  • 3. Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Feuerecker B, Chantadisai M, Allmann A, Tauber R, Allmann J, Steinhelfer L, Rauscher I, Wurzer A, Wester HJ, Weber WA, d'Alessandria C, Eiber M.
    J Nucl Med; 2022 Jun 01; 63(6):833-839. PubMed ID: 34531260
    [Abstract] [Full Text] [Related]

  • 4. Enhancing Treatment Efficacy of 177Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies.
    Kuo HT, Merkens H, Zhang Z, Uribe CF, Lau J, Zhang C, Colpo N, Lin KS, Bénard F.
    Mol Pharm; 2018 Nov 05; 15(11):5183-5191. PubMed ID: 30251544
    [Abstract] [Full Text] [Related]

  • 5. 177Lu-Labeled Albumin-Binder-Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio.
    Kuo HT, Lin KS, Zhang Z, Uribe CF, Merkens H, Zhang C, Bénard F.
    J Nucl Med; 2021 Apr 05; 62(4):521-527. PubMed ID: 32859704
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and Preclinical Evaluation of 177Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer.
    Wurzer A, Kunert JP, Fischer S, Felber V, Beck R, Rose F, D'Alessandria C, Weber W, Wester HJ.
    J Nucl Med; 2022 Oct 05; 63(10):1489-1495. PubMed ID: 35086894
    [Abstract] [Full Text] [Related]

  • 7. Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies.
    Wurzer A, De Rose F, Fischer S, Schwaiger M, Weber W, Nekolla S, Wester HJ, Eiber M, D'Alessandria C.
    EJNMMI Radiopharm Chem; 2024 Feb 26; 9(1):18. PubMed ID: 38407630
    [Abstract] [Full Text] [Related]

  • 8. Comparison of novel PSMA-targeting [177Lu]Lu-P17-087 with its albumin binding derivative [177Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study.
    Li L, Wang J, Wang G, Wang R, Jin W, Zang J, Sui H, Jia C, Jiang Y, Hong H, Zhu L, Alexoff D, Ploessl K, Kung HF, Zhu Z.
    Eur J Nucl Med Mol Imaging; 2024 Jul 26; 51(9):2794-2805. PubMed ID: 38658392
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic Multidose Preparation of a Ready-to-Use 177Lu-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy.
    Chakraborty A, Mitra A, Tawate M, Sahoo S, Lad S, Rakshit S, Gaikwad S, Basu S, Shimpi H, Banerjee S.
    Cancer Biother Radiopharm; 2021 Oct 26; 36(8):682-692. PubMed ID: 34402687
    [Abstract] [Full Text] [Related]

  • 10. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
    Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, Bal C.
    Nucl Med Commun; 2017 Jan 26; 38(1):91-98. PubMed ID: 27782913
    [Abstract] [Full Text] [Related]

  • 11. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside.
    Arbuznikova D, Klotsotyra A, Uhlmann L, Domogalla LC, Steinacker N, Mix M, Niedermann G, Spohn SKB, Freitag MT, Grosu AL, Meyer PT, Gratzke C, Eder M, Zamboglou C, Eder AC.
    Theranostics; 2024 Jan 26; 14(6):2560-2572. PubMed ID: 38646643
    [Abstract] [Full Text] [Related]

  • 12. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
    Kuo HT, Lin KS, Zhang Z, Zhang C, Merkens H, Tan R, Roxin A, Uribe CF, Bénard F.
    Theranostics; 2022 Jan 26; 12(14):6179-6188. PubMed ID: 36168623
    [Abstract] [Full Text] [Related]

  • 13. Radiohybrid Ligands: A Novel Tracer Concept Exemplified by 18F- or 68Ga-Labeled rhPSMA Inhibitors.
    Wurzer A, Di Carlo D, Schmidt A, Beck R, Eiber M, Schwaiger M, Wester HJ.
    J Nucl Med; 2020 May 26; 61(5):735-742. PubMed ID: 31862804
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
    Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, Kulkarni HR, Lassmann M, Klette I, Eiber M, Schwaiger M, Wester HJ.
    J Nucl Med; 2015 Aug 26; 56(8):1169-76. PubMed ID: 26089548
    [Abstract] [Full Text] [Related]

  • 16. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA, Benešová M, Schibli R, Müller C.
    Mol Pharm; 2018 Jun 04; 15(6):2297-2306. PubMed ID: 29684274
    [Abstract] [Full Text] [Related]

  • 17. Safety, Biodistribution, and Radiation Dosimetry of 18F-rhPSMA-7.3 in Healthy Adult Volunteers.
    Tolvanen T, Kalliokoski K, Malaspina S, Kuisma A, Lahdenpohja S, Postema EJ, Miller MP, Scheinin M.
    J Nucl Med; 2021 May 10; 62(5):679-684. PubMed ID: 33067338
    [Abstract] [Full Text] [Related]

  • 18. Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression.
    Wen X, Xu P, Zeng X, Liu J, Du C, Zeng X, Cheng X, Wang X, Liang Y, Zhao T, Yang H, Li H, Meng L, Fang J, Liu H, Zhou Z, Zhang J, Zhang X, Guo Z, Chen X.
    Eur J Nucl Med Mol Imaging; 2023 Jul 10; 50(9):2846-2860. PubMed ID: 37097443
    [Abstract] [Full Text] [Related]

  • 19. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
    Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, Tritschler S, Stief CG, Kopka K, Haberkorn U, Bartenstein P, Böning G.
    Eur J Nucl Med Mol Imaging; 2016 Jan 10; 43(1):42-51. PubMed ID: 26318602
    [Abstract] [Full Text] [Related]

  • 20. Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates.
    Banerjee SR, Foss CA, Pullambhatla M, Wang Y, Srinivasan S, Hobbs RF, Baidoo KE, Brechbiel MW, Nimmagadda S, Mease RC, Sgouros G, Pomper MG.
    J Nucl Med; 2015 Apr 10; 56(4):628-34. PubMed ID: 25722448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.